Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2023-08-17 00:00:00 ET · period of report 2023-08-14 · accession 0001593968-23-001226 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-08-17 | 2023-08-14 | ALLO | Douglas Earl Martin | GC | A - Grant | $0.00 | +435.8K | 109.0K | New | $0 |
| D | 2023-08-17 | 2023-08-14 | ALLO | Douglas Earl Martin | GC | A - Grant | $0.00 | +960.9K | 960.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-14 | A | A | 326,876 | $0.00 | 435,834 | D | — | — | |
| 2 | Common | Common Stock | 2023-08-14 | A | A | 108,958 | $0.00 | 108,958 | D | — | — | (F1) Constitutes Performance Restricted Stock Units ("PRSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each PRSU upon vesting, 50% shall vest in the event the Company achieves a 30-day weighted average share price of $18 on or before March 22, 2026 and 50% shall vest upon the first marketing approval of a Company product by the US FDA on or before March 22, 2028. |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-08-14 | A | A | 960,854 | $0.00 | 960,854 | D | $4.13 · — to 2033-08-14 | 960,854 Common Stock | (F2) 25% of the shares subject to the stock option shall vest on August 14, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. |